Literature DB >> 17312565

Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.

Andrew F Shorr1, D Ray Lazarus, John H Sherner, William L Jackson, Matthew Morrel, Victoria J Fraser, Marin H Kollef.   

Abstract

OBJECTIVE: To describe the evolving epidemiology of fungal bloodstream infections in critically ill and noncritically ill patients and to identify predictors of infection with non-albicans yeast species.
DESIGN: Retrospective case series.
SETTING: Two academic, tertiary care centers. PARTICIPANTS: All persons during a 4-yr period who developed fungemia.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We initially compared subjects with Candida albicans vs. alternative yeast. In a sensitivity analysis, we compared persons with potentially fluconazole-resistant organisms (Candida glabrata and Candida krusei) to those with other fungi. We also repeated these analyses in the subgroup of persons in the intensive care unit when they developed fungemia. The study cohort included 245 patients (60% in the intensive care unit), and C. albicans accounted for 52% of infections, whereas C. glabrata represented 20% of cases. The distribution of isolates was similar in both intensive care unit patients and those on the wards. In the entire population, no variable, including both previous fluconazole exposure and severity of illness, correlated with the fungemia due to a non-albicans species. In our sensitivity analysis, no factor was independently associated with a potentially fluconazole-resistant yeast. For the subgroup of subjects whose fungemia was diagnosed while they were in the intensive care unit, no variable differentiated C. albicans from non-albicans isolates.
CONCLUSIONS: Non-albicans yeast are common both in the intensive care unit and on the wards. Simple clinical factors do not allow the clinician to effectively identify patients likely infected with non-albicans pathogens or with possible fluconazole-resistant fungi.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312565     DOI: 10.1097/01.CCM.0000259379.97694.00

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  18 in total

1.  Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Authors:  Olivier Lortholary; Marie Desnos-Ollivier; Karine Sitbon; Arnaud Fontanet; Stéphane Bretagne; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

3.  Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note.

Authors:  Anna M Romanelli; Deanna A Sutton; Elizabeth H Thompson; Michael G Rinaldi; Brian L Wickes
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

4.  Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital.

Authors:  L X Bonfietti; M W Szeszs; M R Chang; M A Martins; S R B S Pukinskas; M O Nunes; G H Pereira; A M M Paniago; S U Purisco; M S C Melhem
Journal:  Mycopathologia       Date:  2012-07-21       Impact factor: 2.574

5.  Increase in Candida parapsilosis fungemia in critical care units: a 6-years study.

Authors:  Elif Sahin Horasan; Gülden Ersöz; Musa Göksu; Feza Otag; Ahmet Oner Kurt; Sevim Karaçorlu; Ali Kaya
Journal:  Mycopathologia       Date:  2010-06-04       Impact factor: 2.574

6.  Management of invasive candidiasis in the intensive care unit.

Authors:  E Geoffrey Playford; Jeff Lipman; Tania C Sorrell
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

7.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

Review 8.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

9.  Comparison of albicans vs. non-albicans candidemia in French intensive care units.

Authors:  Olivier Leroy; Jean-Paul Mira; Philippe Montravers; Jean-Pierre Gangneux; Olivier Lortholary
Journal:  Crit Care       Date:  2010-05-27       Impact factor: 9.097

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.